Clinical Study
Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy
Table 4
Effect of oral administration of bLF on patients in test group after 3 months (results represented as mean ± SD values).
| Parameter | Control mean ± SD | LF mean ± SD |
| BUN (mg/dL) | 0.3 ± 2.9 | 4.8 ± 3.14* | Serum creatinine (mg/dL) | 0.078 ± 0.22 | 0.14 ± 0.26* | AST (IU/L) | 0.306 ± 7.29 | 12.44 ± 13.22* | ALT (IU/L) | 0.88 ± 5.4 | 6.88 ± 11.27* | Serum LF (ng/mL) | 0.002 ± 0.011 | 0.15 ± 0.16* | Serum GST enzyme (ng/mL) | 0.000 ± 0.002 | 0.206 ± 0.089* | INF-γ (pg/mL) | 0.1 ± 0.27 | 1.62 ± 0.66* | WBCs (*103 cell/µL) | 0.146 ± 0.727 | 1.06 ± 1.18* | Platelet (*103/mm3) | 25.40 ± 39.06 | 36.46 ± 12.26* | CEA (ng/mL) | 8.37 ± 23.91 | 13.41 ± 21.91* | RBCs (*106/µL) | 0.111 ± 0.222 | 0.514 ± 0.126* | Neutrophil (%) | 0.93 ± 4.7 | 11.86 ± 1.45* | Hb (g/dL) | 0.52 ± 1.2 | 1.97 ± 0.35* |
|
|
Note: *significant difference .
|